Oct 1 |
Amarin Announces Two Upcoming Investor Events
|
Sep 18 |
Here's Why We're Not At All Concerned With Amarin's (NASDAQ:AMRN) Cash Burn Situation
|
Sep 9 |
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Eur...
|
Aug 22 |
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
|
Aug 8 |
Exploring 3 Undervalued Small Caps In United States With Insider Action
|
Aug 1 |
Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat
|
Jul 31 |
Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript
|
Jul 31 |
Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript
|
Jul 31 |
Amarin Corporation plc 2024 Q2 - Results - Earnings Call Presentation
|
Jul 31 |
Amarin Non-GAAP EPS of $0.01 beats by $0.07, revenue of $67.49M beats by $16.47M
|